You are here:

  1. Home
  2. NICE Guidance
  3. Population groups
  4. Children and teenagers

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2

  • Highly specialised technologies guidance
  • Reference number: HST12
  • Published:  27 November 2019
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Education
  2. Implementation support
  3. Guidance into practice

Tools and resources

Tools and resources to help you put the guidance into practice.

Education

  • Patient/parent questions on the managed access agreement for cerliponase alfa (January 2022)

  • Managed access agreement (PDF 410 KB)

    Published:
    27 November 2019

Implementation support

  • Measuring the use of NICE guidance: NICEimpact children and young people’s healthcare

Guidance into practice

  • About the Into practice guide

  • Practical steps to improving the quality of care and services using NICE guidance

Back to top